FDA 483 - Octapharma AB

Octapharma AB in Stockholm, Sweden, was inspected by the FDA, revealing significant deficiencies in quality control, manufacturing processes, and laboratory operations. The inspection highlighted repeated failures to reject out-of-specification products, inadequate investigations into discrepancies and complaints, and poorly maintained equipment, indicating a systemic lack of adherence to established standards for drug product quality and purity.